RCT: SGLT2 inhibition reduces the risk of hyperkalemia in patients with diabetes and chronic kidney disease.

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial – European Heart Journal (link to abstract – $ for full-text)

Commentary on Twitter

SGLT2 inhibition reduces the risk of serious hyperkalemia in people with diabetic kidney disease, which may enable greater use of RAAS inhibitors in CKD and/or heart failure

New CREDENCE data presented this week at #ESCCongress, now in @ESC_Journals:https://t.co/OEqnXTdBDi pic.twitter.com/zsanEFZVCy

— Brendon Neuen (@brendonneuen) August 23, 2021